Welcome!

News Feed Item

Anaphore Announces Name Change to RuiYi and New Additions to Shanghai Management Team

Moves underscore company focus on the discovery and development of novel biologic therapies in China

LA JOLLA, Calif. and SHANGHAI, Oct. 4, 2012 /PRNewswire/ -- Anaphore announced today that its corporate name has changed to RuiYi.  As part of the company's shift in strategy to the discovery and development of novel biologic therapies in China, including monoclonal antibodies that target G protein coupled receptors (GPCRs), RuiYi has also added three seasoned leaders to its management team in Shanghai.

"RuiYi's new direction will enable us to focus on building our capabilities in Shanghai as we collaborate with a number of innovative drug discovery and development companies to advance our technology," commented Paul Grayson, President and CEO of RuiYi.

New RuiYi Drug Discovery Team

RuiYi also announced today that it has added three key members to its management team to guide its GPCR drug discovery efforts.  Chris Song, Ph.D., joins as Director of Operations, Shouhua (Josh) Xiao, Ph.D., joins as Senior Director of Protein Technology and Lei Shi, Ph.D., joins as Director of Antibody Discovery.

"Chris, Josh and Lei are all exceptionally talented individuals with extensive industry experience that is essential as we continue building a truly outstanding biologics drug discovery company in Shanghai," commented Anke Kretz-Rommel, Ph.D., Vice President of Research and Development, RuiYi.

Dr. Song has more than 20 years of experience in biomedical research and business. Prior to joining RuiYi, he led marketing and sales efforts at OriGene Technologies for its China business initiative. Before OriGene, Chris was with Applied Biosystems China, driving business growth in the pharmaceutical/biotech sector. He also held the position of Business Development Manager at Novartis China, developing business strategy and leading licensing activities for the Oncology Business. Dr. Song received his M.B.A from Stephen M. Ross School of Business at the University of Michigan, his Ph.D. in Molecular Biology and Oncology from the University of Queensland, Australia and a B.Sc from Shandong University, China.

Dr. Xiao has worked in the biotech industry for over 14 years. Prior to joining RuiYi, he was Principal Scientist and led the biologics drug discovery efforts for Oncology at Amgen South San Francisco. Prior to Amgen, he managed the HTS/Molecular Pharmacology group at Tularik and previously worked at Millennium Pharmaceuticals. Dr. Xiao obtained his Ph.D. in Biochemistry from Louisiana State University and conducted his postdoctoral training with Dr. James Manley at Columbia University. He currently serves as Co-chair of the 2011-2012 EC Business & Career Development Committee of the Chinese-American BioPharmaceutical Society.

Dr. Shi joins RuiYi from Centyrex, an internal venture of Johnson & Johnson, where he was responsible for library technology development and lead generation in the area of immunology and oncology. Prior to Centyrex, Dr. Shi was a Senior Research Scientist at Centocor R&D of Johnson and Johnson, where he led a project on developing and validating large scale de novo antibody library technology on a novel phage display platform and was the leading author on the publication and patent on this effort.  Before his career in the biopharmaceutical industry, Dr. Shi conducted his postdoctoral research on innate immunology at Harvard Medical School and Massachusetts General Hospital. He obtained his Ph.D. in Molecular Biology from University of Illinois at Chicago and an Executive Master's degree in Technology Management from the University of Pennsylvania and the Wharton School of Business.

New RuiYi Corporate Headquarters

RuiYi is moving its corporate offices to new space in La Jolla, CA.  Effective November 15, 2012, RuiYi's California-based office will be at:  505 Coast Blvd South, La Jolla, CA 92037.

About RuiYi

RuiYi is focused on the discovery and development of novel biologic therapies in China, including monoclonal antibodies that target G protein coupled receptors (GPCRs).  RuiYi's executive management team has offices in La Jolla, California while all of RuiYi's discovery efforts are located in Shanghai, China.  RuiYi's research facility is located in the Zhangjiang Hi-Tech Park in Pudong Shanghai, China.

For more information please visit www.ruiyibio.com.

SOURCE RuiYi

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Today, we have more data to manage than ever. We also have better algorithms that help us access our data faster. Cloud is the driving force behind many of the data warehouse advancements we have enjoyed in recent years. But what are the best practices for storing data in the cloud for machine learning and data science applications?
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term.
The standardization of container runtimes and images has sparked the creation of an almost overwhelming number of new open source projects that build on and otherwise work with these specifications. Of course, there's Kubernetes, which orchestrates and manages collections of containers. It was one of the first and best-known examples of projects that make containers truly useful for production use. However, more recently, the container ecosystem has truly exploded. A service mesh like Istio addr...
CloudEXPO New York 2018, colocated with DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time t...
Dynatrace is an application performance management software company with products for the information technology departments and digital business owners of medium and large businesses. Building the Future of Monitoring with Artificial Intelligence Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more busi...
DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City and will bring together Cloud Computing, FinTech and Blockchain, Digital Transformation, Big Data, Internet of Things, DevOps, AI, Machine Learning and WebRTC to one location.
SYS-CON Events announced today that DatacenterDynamics has been named “Media Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY. DatacenterDynamics is a brand of DCD Group, a global B2B media and publishing company that develops products to help senior professionals in the world's most ICT dependent organizations make risk-based infrastructure and capacity decisions.
"When you think about the data center today, there's constant evolution, The evolution of the data center and the needs of the consumer of technology change, and they change constantly," stated Matt Kalmenson, VP of Sales, Service and Cloud Providers at Veeam Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. That ...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
Headquartered in Plainsboro, NJ, Synametrics Technologies has provided IT professionals and computer systems developers since 1997. Based on the success of their initial product offerings (WinSQL and DeltaCopy), the company continues to create and hone innovative products that help its customers get more from their computer applications, databases and infrastructure. To date, over one million users around the world have chosen Synametrics solutions to help power their accelerated business or per...
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.